Restore kept at outperform by RBC

RBC Capital Markets analyst Phil Nalbone maintained Restore Medical, Inc. at outperform, speculative risk, with a price target of $7.00 after company results met RBC's lowered expectations. As expected, total sales were flat versus the year-ago quarter at $1.2 million, with U.S. sales of $1.1 million and worldwide sales of $131,000 relative to $432,000 the prior year. Shares of the St. Paul, Minn.-based medical device company were up 0.0815 cents, or 2.16%, at $3.8615. (Nasdaq: REST)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.